The clinical trial collaboration focuses on utilizing remote diagnostic monitoring through the use of precision medicine clinical-grade, cloth-based wearable technology. The goal is to monitor patients with confirmed or suspected COVID-19 with Nanowear’s proprietary and patented cloth-based nanosensors which detect physiological and biomarker changes indicative of clinical deterioration that may require further intervention from the hospital systems.

Nanowear’s digital platform enables a radical leap forward in telemedicine and remote patient diagnostics. When a patient wears SimpleSENSE, Nanowear’s one-size-fits-all adjustable undergarment, physicians can remotely capture and assess multiple physiological signals – including real-time ECG, systolic and diastolic blood pressure, blood flow hemodynamics, respiration, lung volume and fluid, and temperature trends – without the need for an in-person visit or physical touch.

When we talk about telemedicine, we often talk about video conferencing, said Venk Varadan, Co-founder and CEO. But to truly enable remote diagnostics we must incorporate clinical-grade remote monitoring that is affordable, comfortable, and simple for patients to use. Nanowear’s SimpleSENSE replaces a stethoscope, blood pressure cuff, multi-channel Holter monitor, and Capnogram (End-tidal CO2), providing a diagnostic quality monitoring system in a form factor that is easy to ship, easy to wear, and easy for the patient to use. Nanowear’s garment captures 120 million data points per patient per day across cardiac, pulmonary, and circulatory biomarker data, which is transmitted to clinical staff, so that they may make informed and quicker decisions remotely.

The COVID-19 pandemic has transformed healthcare delivery and diagnosis; the traditional experience of a physician physically examining or touching a patient in-person has been altered, perhaps forever, and could have a lasting impact on the future of patient-physician physical interactions expansively from primary care to chronic disease cases.

As New York City, the epicenter of the global coronavirus pandemic, emerges from coronavirus lockdown, health systems are looking for novel technologies like Nanowear to better understand and combat the unprecedented severity of COVID-19. Nanowear is being used to aid in COVID-19 diagnosis to ensure the health and safety of patients and medical professionals.

What we need to understand about COVID-19 is why certain patients develop a cytokine mediated immune response from the virus, said national Principal Investigator of the collaboration, Sameer Jamal, MD, of Hackensack Meridian Health, the largest health system in New Jersey. This resulting inflammation within the circulatory system often leads to severe complications or death, which we have seen first-hand in New York City and the surrounding area. Diagnosis and co-morbidities alone is not enough to determine risk to admitted patients before they need to be transferred to ICU. Nanowear’s SimpleSENSE is giving us an exponential amount of relevant data metrics about the heart and lungs from an all-in-one product that should ultimately enable us to triage lower risk patients and stratify high risk patients.

While the immediate need for hospitals across the US is to remotely diagnose and assess worsening COVID-19 instances from home-to-hospital and hospital-to-home, the virus itself has changed the paradigm for healthcare delivery in general.

The COVID-19 paradigm shift has accelerated healthcare systems’ need to implement staff-contactless monitoring involving acute and chronic disease-related hospitalizations, said John Marshall, MD, Head of Emergency Department at Maimonides Medical Center in Brooklyn, New York. “The continuity of in-patient monitoring, patient-to-home monitoring, and at-home monitoring across 8-10 biomarkers with a very easy-to-use product is what makes Nanowear’s solution compelling and unique.

Unlike consumer-grade wearable garments, smartwatches, smartrings or limited-metric adhesive patches, Nanowear’s textile-embedded multi-parameter nanosensors are clinical-grade, analyzing multiple cardiac, pulmonary, and circulatory biomarkers, creating a holistic personalized digital signature for each patient. The garment transmits these diagnostic health signals to a mobile application and physician portal, enabling healthcare professionals to assess a wide range of medical conditions, from diabetes, high blood pressure and congestive heart failure (CHF), to acute illness, discomfort, and stress.

Nanowear’s core of cloth-nanotechnology sensors is a differentiator from smartwatches, adhesive patches, and other medical or consumer wearables, said Suraj Kapa, MD, of Mayo Clinic. With billions of touchpoints per centimeter and large vectors across the heart and lungs, Nanowear’s skin-to-impedance barrier is lower than other wearable sensors, resulting in location-agnostic, high signal-to-noise raw data from basic skin contact. The breadth of metrics, quality and quantity of data, and comfortable user experience are key for machine learning algorithms in various diagnostic verticals, even beyond healthcare.

Nanowear’s proprietary and patented cloth-based nanotechnology was invented by Co-founder and Chief Innovation Officer, Dr. Vijay Varadan and founding engineers, Dr. Pratyush Rai, Prashanth Shyam Kumar, Mouli Ramasamy and Dr. Gyanesh Mathur. SimpleSENSE achieved first-on-man status in late 2019 in the NanoSENSE Heart Failure validation study led by national Principal Investigator John Boehmer, MD, Director of Penn State Hershey Medical Center’s Heart and Vascular Institute. Hackensack Meridian Health Systems and Medical University of South Carolina are also participating in the NanoSENSE Heart Failure study.

Nanowear has submitted its SimpleSENSE device and mobile platform to FDA for Class II 510(k) clearance. SimpleSENSE is not yet FDA-cleared and currently not intended to mitigate, prevent, treat, cure or diagnose any disease or condition.

Apple Watch has become an indispensable part of our customers’ everyday lives, from helping users stay connected to the people and information they care about, to inspiring them to live a better and more active day, said Jeff Williams, Apple’s chief operating officer. watchOS 6 extends our commitment to helping users better manage their health and fitness with powerful and personal new tools.

Health and Fitness

The new Cycle Tracking app gives women the ability to log important information related to their menstrual cycles and see predicted timing for their next period and fertile window using the convenience of Apple Watch. The daily log function enables the quick addition of information related to the menstrual cycle, including current period, flow, symptoms, results from ovulation prediction kits and other elements of fertility tracking. The new Cycle Tracking feature is also available in the Health app on iPhone with iOS 13.

Maintenance of hearing health positively impacts the quality of life and studies have shown that hearing loss has been associated with cognitive decline.
With the optimal position of Apple Watch on the wrist, the Noise app helps users understand the sound levels in environments such as concerts and sporting events that could negatively impact hearing. As the sound levels change, the app’s decibel meter moves in real time. The watch can send a notification if the decibel level reaches 90 decibels, which can begin to impact hearing after four hours per week of exposure at this level, according to the World Health Organization.

Read the full Press Release at apple.com

In November 2017, we launched the report ‘The future awakens: Life sciences and health care predictions 2022’. Our intention was to provide an unashamedly positive and provocative view of how the world may look in 2022, if the constraints that many believe impede adoption of innovation can be overcome.

The report acknowledges the increasing pace and scale of innovation in healthcare over the past three years or so, and how new science, automation and robotics will impact the future of work. It also highlights how these developments will impact the life sciences and health care industries’ business, operating and financing models.

Here are six predictions for 2022 – both evolutionary and revolutionary

1. The quantified self is alive and well: the genome generation is more informed and engaged in managing its own health.
In 2022, individuals are better informed about their genetic profile, the diseases they have, or may develop, and the effectiveness of health interventions. People are also more engaged in improving their own health, and their expectations of health care are high for themselves and their loved ones.

2. The culture in health care is transformed by digital technologies: smart health care is delivering more cost-effective, patient-centred care.
In 2022, a growing number of healthcare services are delivered more effectively at home or in outpatient ambulatory facilities and patients with complex and acute inpatient needs are treated in ‘smart’, digitally-enabled hospitals. Clinical roles have been optimised and staff are using cognitive technologies to deliver more seamless, integrated care, designed around patients’ needs.

3. The life sciences industry is industrialised: advanced cognitive technologies have improved the productivity, speed and compliance of core processes
In 2022, pharma uses a lean operating model to generate funding for R&D and deliver more cost-effective medical innovations. The ‘industrialisation’ of pharma has led to productivity increases across functions and geographies. Companies have moved through three phases of evolution – first codifying and standardising processes, then automating them, and now deploying artificial intelligence (AI) and machine learning to increase productivity still further (Figure 3). This step change has improved compliance materially and enhanced the predictability of core processes.

4. Data is the new health care currency: AI and real-world evidence are unlocking value in health data
In 2022, health care data is a national infrastructure priority and critical business asset attracting significant funding. Real-world data (RWD) is providing the information needed to enable researchers to develop more precision medicine and clinicians to predict patients’ responses to treatments. Clinical guidelines and experiences have been turned into computer algorithms to support clinicians and payers to find the best treatments. Pharma companies are using RWD to develop better treatments, launch them faster and price them according to improvements in health outcomes.

5. The future of medicine is here and now: exponential advances in life-extending and precision therapies are improving outcomes
In 2022, insights from human genetics, precision and personalised medicine, have transformed health care, bringing value through innovative biotechnology and requiring the health system to move from looking at the average patient to looking at the individual patient. AI has revolutionised health care through mining medical records, designing treatment plans, speeding up medical imaging and drug creation. Outcomes-based payment strategies are common for treatments where patient populations and endpoints are well defined.

6. New entrants are disrupting health care: the boundaries between stakeholders have become increasingly blurred
In 2022, the health care landscape has changed significantly with non-traditional health care players using their brand, engineering expertise and knowledge of customers to disrupt the health care landscape. These new entrants have partnered with traditional providers to deliver a more customer-focused experience of health care. Many companies have realised that only by working together can they succeed, requiring new skills, behaviours and standards to be adopted in each organisation with more porous boundaries, especially around data sharing.